Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease
NCT ID: NCT01364688
Last Updated: 2011-06-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
80 participants
INTERVENTIONAL
2011-05-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients
NCT01512862
Vitamin D and Carboxy PTH Fragments in Coronary Calcification
NCT00502268
Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease
NCT00395382
Comparison of Serum Calcium Level Between Preoperative Vitamin D and Non-vitamin D Regimen of Total Parathyroidectomy in End-stage Renal Failure Patients in Rajavithi Hospital
NCT04967469
Intravenous Sodium Thiosulfate on Coronary Calcification in Patients on Hemodialysis
NCT00720772
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
oral alfacalcidol
oral alfacalcidol
Oral alfacalcidol 0.5 microgram per day
Control
No drug
no drug
no drug
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
oral alfacalcidol
Oral alfacalcidol 0.5 microgram per day
no drug
no drug
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* PTH above the upper limit of normal
* serum calcium and phosphate below the upper limit of normal
Exclusion Criteria
* receive elemental calcium\>500 mg/day
* currently taking active vitamin D, oral calcium with elemental calcium\>500 mg/day or bisphosphonate
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ramathibodi Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Division of Nephrology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Phayathai, Bangkok, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
25-05-2011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.